The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Hims & Hers Health Inc (NYSE: HIMS) closed at $50.38 in the last session, up 0.78% from day before closing price of $49.99. In other words, the price has increased by $0.78 from its previous closing price. On the day, 22.02 million shares were traded. HIMS stock price reached its highest trading level at $51.0604 during the session, while it also had its lowest trading level at $48.5.
Ratios:
We take a closer look at HIMS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 47.93. For the most recent quarter (mrq), Quick Ratio is recorded 1.32 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65.
TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 16 ’25 when Dudum Andrew sold 47,534 shares for $50.25 per share. The transaction valued at 2,388,817 led to the insider holds 190,126 shares of the business.
Dudum Andrew sold 2,792 shares of HIMS for $141,217 on Jul 16 ’25. The Chief Executive Officer now owns 92,313 shares after completing the transaction at $50.58 per share. On Jul 16 ’25, another insider, Dudum Andrew, who serves as the Officer of the company, bought 50,326 shares for $50.27 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 11276656640 and an Enterprise Value of 10898714624. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 73.33, and their Forward P/E ratio for the next fiscal year is 52.92. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.32 while its Price-to-Book (P/B) ratio in mrq is 20.51. Its current Enterprise Value per Revenue stands at 6.108 whereas that against EBITDA is 79.161.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.07, which has changed by 1.4768927 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $13.47. The 50-Day Moving Average of the stock is -6.09%, while the 200-Day Moving Average is calculated to be 38.41%.
Shares Statistics:
According to the various share statistics, HIMS traded on average about 46.68M shares per day over the past 3-months and 26008280 shares per day over the past 10 days. A total of 215.21M shares are outstanding, with a floating share count of 190.71M. Insiders hold about 14.80% of the company’s shares, while institutions hold 70.40% stake in the company. Shares short for HIMS as of 1749772800 were 61690896 with a Short Ratio of 1.46, compared to 1747267200 on 62338753. Therefore, it implies a Short% of Shares Outstanding of 61690896 and a Short% of Float of 34.23.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Hims & Hers Health Inc (HIMS) in the stock market.The consensus estimate for the next quarter is $0.26, with high estimates of $0.29 and low estimates of $0.22.
Analysts are recommending an EPS of between $1.16 and $0.87 for the fiscal current year, implying an average EPS of $1.04. EPS for the following year is $1.38, with 5.0 analysts recommending between $1.82 and $1.08.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $550.06M. It ranges from a high estimate of $563.59M to a low estimate of $540.01M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $315.65MFor the next quarter, 9 analysts are estimating revenue of $587.04M. There is a high estimate of $611.9M for the next quarter, whereas the lowest estimate is $549.7M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.39B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.82B in the next fiscal year. The high estimate is $3.02B and the low estimate is $2.55B.
